Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

Eva Ciruelos GilAlvaro MontañoCésar A RodríguezEncarnación González-FloresAna LluchLaia GarrigósVanesa QuirogaAntonio AntónDiego MalónJose I ChacónMontserrat VelascoLucía Gonzalez-CortijoLaura JolisMaría J EcharriMontse MuñozTomás PascualYolanda AmigoMaribel CasasEva CarrascoAna Casas

Published in: European journal of cancer care (2020)

SC-t is preferred with no safety impact.

Keyphrases

metastatic breast cancer
phase iii
end stage renal disease
clinical trial
chronic kidney disease
ejection fraction
open label
newly diagnosed
high dose
prognostic factors
peritoneal dialysis
low dose